Tvardi Therapeutics, Inc. TVRD NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

47/100

2/6 Pass

SharesGrow Intrinsic Value

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Tvardi Therapeutics, Inc. (TVRD) has a negative trailing P/E of -2.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -49.30%.

Criteria proven by this page:

VALUE (75/100, Pass) — analyst target implies upside (+29.7%).
Trailing Earnings Yield -49.30% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
Analyst consensus target $4.50 (+29.7% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 46/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

47/100

SG Score

View full scorecard →

✓

VALUE

75/100

Price-to-Earnings & upside

Proven by this page

FUTURE

46/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

→ Health

MOAT

46/100

→ Income

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — TVRD

Valuation Multiples

P/E (TTM)-2.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio1.31

P/S Ratio10.75

EV/EBITDA-0.3

Per Share Data

EPS (TTM)$-1.45

Book Value / Share$2.25

Revenue / Share$0.28

FCF / Share$-2.52

Yields & Fair Value

Earnings Yield-49.30%

Dividend Yield0.00%

Analyst Target$4.50 (+29.7%)

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2020	0.8	0.00	0.03	0.05	-
2021	-0.1	0.00	0.03	0.30	-
2022	-0.5	0.01	-1.02	1.09	-
2023	-0.4	0.02	-0.74	2.19	-
2024	-0.1	0.00	-1.62	1.04	-
2025	-1.8	0.02	1.52	0.00	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2022	$-2.20	$0.00	$-20.54M	-
2023	$-1.85	$0.00	$-17.35M	-
2024	$-46.59	$7.14M	$-70.87M	-993%
2025	$-3.26	$0.00	$-18.21M	-

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-2.02	$-3.00 – $-1.62	$0.00	$0.00 – $0.00	4
2027	$-3.11	$-3.81 – $-2.46	$0.00	$0.00 – $0.00	4
2028	$-4.35	$-8.17 – $-0.52	$1.17M	$1.17M – $1.17M	2
2029	$-3.57	$-3.57 – $-3.57	$18.2M	$18.2M – $18.2M	1
2030	$-4.27	$-4.27 – $-4.27	$0.00	$0.00 – $0.00	1